![Company Overview - Peregrine Pharmaceuticals, Inc.](http://s1.studyres.com/store/data/007830182_1-3f99d38ace2f165c670f9428888856fe-300x300.png)
Company Overview - Peregrine Pharmaceuticals, Inc.
... programs, and to capture the value that we believe exists in new bavituximab therapeutic combinations and indications. For more information about bavituximab, click here . For more information on antibody mediated blockade of the phosphatidylserine (PS) signaling pathway, ...
... programs, and to capture the value that we believe exists in new bavituximab therapeutic combinations and indications. For more information about bavituximab, click here . For more information on antibody mediated blockade of the phosphatidylserine (PS) signaling pathway, ...
December 2015 Monitoring International Trends
... The NBA monitors international developments that may influence the management of blood and blood products in Australia. Our focus is on: Potential new product developments and applications; Global regulatory and blood practice trends; Events that may have an impact on global supply, demand and ...
... The NBA monitors international developments that may influence the management of blood and blood products in Australia. Our focus is on: Potential new product developments and applications; Global regulatory and blood practice trends; Events that may have an impact on global supply, demand and ...
Article PDF
... to a second drug, whether they switched within class or to another class. In level two of the study, patients who chose to switch to a new drug after taking the SSRI citalopram were randomized either to another SSRI, sertraline (Zoloft); to the SNRI venlafaxine (Effexor); or to another dual-action d ...
... to a second drug, whether they switched within class or to another class. In level two of the study, patients who chose to switch to a new drug after taking the SSRI citalopram were randomized either to another SSRI, sertraline (Zoloft); to the SNRI venlafaxine (Effexor); or to another dual-action d ...
Optic Neuritis
... 3. Any further information you need to know in the examination 4. What is your provisional diagnosis? 5. What is your role as an ER physician in this case??? Who treats such a case 6. How does the ophthalmologist manage such a case? ...
... 3. Any further information you need to know in the examination 4. What is your provisional diagnosis? 5. What is your role as an ER physician in this case??? Who treats such a case 6. How does the ophthalmologist manage such a case? ...
October 2012 Monitoring International Trends
... 1. Products Here the NBA follows the progress in research and clinical trials that may within a reasonable timeframe make new products available, or may lead to new uses or changes in use for existing products. a. Clotting factors. Biogen Idec and Swedish Orphan Biovitrum (Sobi), have designed the ...
... 1. Products Here the NBA follows the progress in research and clinical trials that may within a reasonable timeframe make new products available, or may lead to new uses or changes in use for existing products. a. Clotting factors. Biogen Idec and Swedish Orphan Biovitrum (Sobi), have designed the ...
Clinical Alert
... aged 75 years and older who did not have dementia at baseline were identified. Of these patients, 4% used PPIs regularly (e.g. at least one prescription per quarter) during at least one 12- to 18-month interval during the study period. After adjusting for confounders, including age, depression, stro ...
... aged 75 years and older who did not have dementia at baseline were identified. Of these patients, 4% used PPIs regularly (e.g. at least one prescription per quarter) during at least one 12- to 18-month interval during the study period. After adjusting for confounders, including age, depression, stro ...
11th International Verticillium Symposium 2013
... characterising those genes that have been transcribed into proteins during key development stages, such as germination of microsclerotia and infection. These studies are still in early days; only preliminary results were reported from several researchers in Spain, Germany and China. Several studies ...
... characterising those genes that have been transcribed into proteins during key development stages, such as germination of microsclerotia and infection. These studies are still in early days; only preliminary results were reported from several researchers in Spain, Germany and China. Several studies ...
Draft Pharmacovigilance paper - European Public Health Alliance
... make informed choices; by designing prioritised information leaflet for patients, to help them understand the most frequent and serious risks and how to avoid them. Therefore, the EMEA pharmacovigilance database should be available to health professionals, consumer and other organisations with a leg ...
... make informed choices; by designing prioritised information leaflet for patients, to help them understand the most frequent and serious risks and how to avoid them. Therefore, the EMEA pharmacovigilance database should be available to health professionals, consumer and other organisations with a leg ...
Faculty of Infectious and Tropical Diseases
... anthropologists and social scientists, clinical scientists, public health engineers and geographers. This range of expertise provides us with a battery of tools for focusing on the control of diseases that are insect-borne, water-borne or associated with poor hygiene – mostly in developing countries ...
... anthropologists and social scientists, clinical scientists, public health engineers and geographers. This range of expertise provides us with a battery of tools for focusing on the control of diseases that are insect-borne, water-borne or associated with poor hygiene – mostly in developing countries ...
March 24, 2017 AnGes MG, Inc. Investigational New Drug (IND
... New Drug (IND) application to the U.S. Food and Drug Administration (FDA) for a clinical trial with NF-kappaB decoy oligo DNA (hereinafter, NF-kappaB decoy), which the company is planning to conduct in the United States for the treatment of discogenic lower back pain (DLBP). ...
... New Drug (IND) application to the U.S. Food and Drug Administration (FDA) for a clinical trial with NF-kappaB decoy oligo DNA (hereinafter, NF-kappaB decoy), which the company is planning to conduct in the United States for the treatment of discogenic lower back pain (DLBP). ...
Kigali Institute of Science and Technology Institut des Sciences et de
... examples that fulfill the epidemiological status of infectious diseases? (3 marks) 2. In the characteristic pattern of the course of an epidemiologically qualified infectious diseases, what are the following periods called? (1 marks each) a) The period between the pathogen’s entry into the host’s bo ...
... examples that fulfill the epidemiological status of infectious diseases? (3 marks) 2. In the characteristic pattern of the course of an epidemiologically qualified infectious diseases, what are the following periods called? (1 marks each) a) The period between the pathogen’s entry into the host’s bo ...
Price 3s. 6d. (Also published in French and Spanish.) Infectious
... the consequences of infection are likely to be more serious in a malnourished host than in a well-nourished one. The simultaneous presence of infection and malnutrition may result in an interaction more serious than the additive effects of the two factors working independently. Primary herpes simple ...
... the consequences of infection are likely to be more serious in a malnourished host than in a well-nourished one. The simultaneous presence of infection and malnutrition may result in an interaction more serious than the additive effects of the two factors working independently. Primary herpes simple ...
Bacterial Disease in Humans
... Molecular dignostic polymerase chain reaction assays for the detection of bacterial DNA Amplified mycobacterium tuberculosis direct test :is highly sensitive and specific when used to test smears positive for acid-fast bacilli (AFB), which was approved by the FDA in 1996 ...
... Molecular dignostic polymerase chain reaction assays for the detection of bacterial DNA Amplified mycobacterium tuberculosis direct test :is highly sensitive and specific when used to test smears positive for acid-fast bacilli (AFB), which was approved by the FDA in 1996 ...
Hepatitis C Virus (HCV) Medication Prior Authorization Victrelis
... tests before starting, during, and after completing treatment as ordered by my healthcare provider. I understand that for the medication to work, it is important that I take my medication each day for the entire course of treatment. I understand the importance to not drink alcohol or use ill ...
... tests before starting, during, and after completing treatment as ordered by my healthcare provider. I understand that for the medication to work, it is important that I take my medication each day for the entire course of treatment. I understand the importance to not drink alcohol or use ill ...
Your guide to getting involved in clinical trials
... to better understand how well the experimental medicine works. In clinical trials, experimental treatments are often compared with placebo to assess the treatment’s effectiveness, as well as its safety and tolerability. In most longer term clinical studies, you will be able to remain on your current ...
... to better understand how well the experimental medicine works. In clinical trials, experimental treatments are often compared with placebo to assess the treatment’s effectiveness, as well as its safety and tolerability. In most longer term clinical studies, you will be able to remain on your current ...
Expanded Access IDE (“Compassionate Use”)
... lifethreatening or to immediately result in death. Serious diseases or conditions: Diseases or conditions involving risk or serious irreversible morbidity, such as sight-threatening or limb-threatening conditions, paralysis, stroke. (2) There is no generally acceptable alternative for treating the p ...
... lifethreatening or to immediately result in death. Serious diseases or conditions: Diseases or conditions involving risk or serious irreversible morbidity, such as sight-threatening or limb-threatening conditions, paralysis, stroke. (2) There is no generally acceptable alternative for treating the p ...
INCIVO - ELPA Homepage
... patients with a chronically or seriously debilitating disease or a lifethreatening disease, and who cannot be treated satisfactorily by an authorised medicinal product in the European Union. The medicinal product is either the subject of a marketing application or is undergoing clinical trials, and ...
... patients with a chronically or seriously debilitating disease or a lifethreatening disease, and who cannot be treated satisfactorily by an authorised medicinal product in the European Union. The medicinal product is either the subject of a marketing application or is undergoing clinical trials, and ...
Gugulipid (Gum Guggul)
... LDL to HDL-cholesterol ratio, in a manner that is associated with a reduced risk of heart disease and related cardiovascular disorders. One of these trials tested Gugulipid against the cholesterol lowering drug clofibrate, in a study involving 228 hypercholesterolemic patients. Results showed that ...
... LDL to HDL-cholesterol ratio, in a manner that is associated with a reduced risk of heart disease and related cardiovascular disorders. One of these trials tested Gugulipid against the cholesterol lowering drug clofibrate, in a study involving 228 hypercholesterolemic patients. Results showed that ...
chapter 20 immunodeficiency
... Inheritance: This disorder can be caused by several different genetic defects, one of which is controlled by an X-linked gene; symptoms appear at about two years of age. Treatment: antibiotic therapy for infections. COMPLEMENT DEFICIENCIES A variety of genetic deficiencies of complement components ...
... Inheritance: This disorder can be caused by several different genetic defects, one of which is controlled by an X-linked gene; symptoms appear at about two years of age. Treatment: antibiotic therapy for infections. COMPLEMENT DEFICIENCIES A variety of genetic deficiencies of complement components ...
Drug Development Tutorial 4: Early phase study design and protocol
... A biological molecule found in blood, other body fluids, or tissues that is a sign of a normal or abnormal process, or of a condition or disease. Can also be a biological molecule being examined to see if the anti-cancer treatment is having a biological effect. ...
... A biological molecule found in blood, other body fluids, or tissues that is a sign of a normal or abnormal process, or of a condition or disease. Can also be a biological molecule being examined to see if the anti-cancer treatment is having a biological effect. ...
Inflammation and infectious etiologies
... Important for laboratory to be aware of suspicion of these organisms so that adequate culture techniques may be employed. Specialized media are not required for culture of members of either group but the use of semi-selective media may increase isolation rates in the presence of more rapidly growing ...
... Important for laboratory to be aware of suspicion of these organisms so that adequate culture techniques may be employed. Specialized media are not required for culture of members of either group but the use of semi-selective media may increase isolation rates in the presence of more rapidly growing ...
Three Basic Points
... potential as an anti-addictive agent. • Cost to conduct this research difficult to estimate, but assuming $50,000 average per study total equals more than $10 million. However, most are preclinical studies. ...
... potential as an anti-addictive agent. • Cost to conduct this research difficult to estimate, but assuming $50,000 average per study total equals more than $10 million. However, most are preclinical studies. ...
Interferon-c therapy in two patients with progressive chronic pulmonary aspergillosis CASE STUDY
... Aspergillus-related lung disease and the role of adjunctive cytokine therapy, such as IFN-c [10, 16, 17], in patients with impaired IFN-c immunity and progressive disease despite appropriate antifungal therapy needs to be clarified. The results of this preliminary study are consistent with other fin ...
... Aspergillus-related lung disease and the role of adjunctive cytokine therapy, such as IFN-c [10, 16, 17], in patients with impaired IFN-c immunity and progressive disease despite appropriate antifungal therapy needs to be clarified. The results of this preliminary study are consistent with other fin ...